Primary Non-Hodgkin’s Lymphoma of Stomach: To Report 54 Patients and Analysis of Major Reported Series

Table 2

Univariate analysis of prognostic factors for clinical outcome.

Prognostic factors	Patients’ number	5-year DFS (%)	𝑃 value	5-year OS (%)	𝑃 value
WHO performance score
0-1	45	73.9	<0.001	76.2	<0.001
2	5	00.0		00.0
3	4	00.0		00.0
Sex
Female	29	61.8	0.742	66.8	0.923
Male	25	68.1		67.3
Age
≤50 years	28	73.9	0.097	79.6	0.034
>50 years	26	55.2		49.1
Ann Arbor stage
I	33	73.2	0.071	75.1	0.027
II	15	59.5		70.1
III	5	40.0		25.0
IV	1	00.0		00.0
Histology
DLBC	36	61.2	0.645	59.5	0.405
MALT	14	71.4		77.9
Others	4	100.0		100.0
Primary tumor size
1–5 cm	13	61.5	0.412	75.0	0.182
6–9 cm	21	72.8		75.9
≥10 cm	20	58.9		50.5
B symptoms
No	36	78.8	0.001	77.8	0.013
Yes	18	36.4		40.6
Serum LDH level
Normal	34	93.1	<0.001	92.6	<0.001
Elevated	20	28.7		34.0
Histological grade
I	27	64.0	0.977	66.4	0.951
II	13	69.2		76.2
III	14	64.3		61.9
Treatment modality
Surgery + CT ± RT	44	61.5	0.387	64.7	0.606
CT and/or RT	10	80.0		80.0
Radiation dose
No RT	7	34.3	0.236	41.7	0.169
<30 Gy	11	61.4		47.7
30–40 Gy	26	75.4		80.7
>40 Gy	10	60.0		60.0
IPI
0-1 risk factor	35	84.4	<0.001	89.2	<0.001
2 risk factor	6	33.3		25.0
≥3 risk factor	13	16.2		13.6
Location
Proximal	27	67.3	0.791	72.1	0.623
Distal	24	61.4		61.7
Diffuse involvement	3	66.7		66.7
All patients	54	64.7		67.0	—

DFS: disease-free survival; OS: overall survival; CT: chemotherapy; RT: radiotherapy; IPI: International Prognostic Index.